Product
[18F]PI-2620
4 clinical trials
5 indications
Indication
Alzheimer's diseaseIndication
Alzheimer diseaseIndication
Mild Traumatic Brain InjuryIndication
Cognitively NormalIndication
Mild Cognitive ImpairmentClinical trial
An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase 1 Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's DiseaseStatus: Completed, Estimated PCD: 2023-06-27
Clinical trial
Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain InjuryStatus: Active (not recruiting), Estimated PCD: 2022-05-12
Clinical trial
Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjectives With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's DiseaseStatus: Completed, Estimated PCD: 2021-02-28